WAYNE, PA, July 30, 2004 –FemmePharma, Inc. announced today its Board of Directors has approved the selection of Ernst & Young as the Company’s independent auditors. “After reviewing several firms, we are confident the world-wide experience and reputation Ernst & Young brings will provide FemmePharma with an excellent partner as it continues to execute its business strategy,” said Kevin Flanagan, a Director of the Company and Chairman of its Audit Committee.
About FemmePharma, Inc.
FemmePharma was founded by Gerianne Tringali DiPiano in 1996 to target needs within the estimated $70 billion women’s healthcare pharmaceutical market. The Company is in a Phase III trial for FP1096, a new investigational treatment for endometriosis, and is preparing for its Phase II trial for its drug to treat female urinary incontinence.
FemmePharma is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a woman’s physiology, with an eye toward the changing needs of women throughout their lives. The company has a number of drugs in development based on its proprietary technologies, including a new therapeutic option for mastalgia. For more information about FemmePharma, please visit its website at www.femmepharmainc.com.